Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019

Emerging Infectious Diseases

Volumn 25, Issue 11, 2019, Pages 2108-2111

  Takashita, Emi ^a   Ichikawa, Masataka ^b   Morita, Hiroko ^a   Ogawa, Rie ^a   Fujisaki, Seiichiro ^a   Shirakura, Masayuki ^a   Miura, Hideka ^a   Nakamura, Kazuya ^a   Kishida, Noriko ^a   Kuwahara, Tomoko ^a   Sugawara, Hiromi ^a   Sato, Aya ^a   Akimoto, Miki ^a   Mitamura, Keiko ^c   Abe, Takashi ^d   Yamazaki, Masahiko ^e   Watanabe, Shinji ^a   Hasegawa, Hideki ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Ichikawa Children's Clinic   (Japan)

^c Public Interest Foundation Corporation Life Extension Laboratory Attached Eiju General Hospital   (Japan)

^d Abe Clinic   (Japan)

^e Zama Children's Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; BALOXAVIR; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG SENSITIVITY; FEVER; GENE MUTATION; HUMAN; IC50; INFANT; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); NASOPHARYNGEAL ASPIRATION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS TRANSMISSION; WHOLE GENOME SEQUENCING; ADOLESCENT; ADULT; DISEASE PREDISPOSITION; DRUG EFFECT; GENETICS; INFLUENZA; JAPAN; MIDDLE AGED; MUTATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DISEASE SUSCEPTIBILITY; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; JAPAN; MIDDLE AGED; MUTATION; OXAZINES; PYRIDINES; THIEPINS; TRIAZINES; YOUNG ADULT;

EID: 85073073460     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2511.190757     Document Type: Article

References (11)

1. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al.; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379:913-23. https://doi.org/10.1056/NEJMoa1716197
2. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8:9633. https://doi.org/10.1038/ s41598-018-27890-4
3. Shionogi & Co. Ltd. Research and development at Shionogi. 2019 Mar 14 [cited 2019 May 27]. http://www.shionogi.co.jp/en/ir/pdf/e_p190314.pdf
4. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9:3026. https://doi.org/10.3389/fmicb.2018.03026
5. Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S, Shirakura M, et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill. 2019;24. http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1900170
6. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87:369-74.
7. Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al.; On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24. http://dx.doi.org/10.2807/1560-7917.ES.2019.24.3.1800698
8. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65. https://doi.org/10.1016/S0140-6736(04)16934-1
9. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-33. https://doi.org/10.1097/00006454-200102000-00002
10. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291-300. https://doi.org/10.1016/S1473-3099(09) 70069-6
11. Lau LL, Cowling BJ, Fang VJ, Chan KH, Lau EH, Lipsitch M, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis. 2010;201:1509-16. https://doi.org/10.1086/652241